2025 年 06 月 29 日 行业周报 看好/维持 医药 医药 板块出现缩量上涨，持续看好创新药（附 PCSK9 靶点研究）(2025.06.23-2025.06.29) 走势比较 推荐公司及评级 | 君实生物 | 买入 | | --- | --- | | 华领医药-B | 买入 | | 奥锐特 | 买入 | | 同和药业 | 买入 | | 阳光诺和 | 买入 | | 泓博医药 | 买入 | | 福元医药 | 买入 | | 三生制药 | 买入 | | 京新药业 | 买入 | | 共同药业 | 增持 | | 亿帆医药 | 买入 | | 诺诚健华 | 买入 | | 诺思格 | 买入 | | 奥翔药业 | 买入 | | 科伦药业 | 买入 | | 国邦医药 | 买入 | | 来凯医药-B | 买入 | | 百利天恒 | 买入 | | 益方生物 | 买入 | | 皓元医药 | 买入 | | 普洛药业 | 买入 | | 信达生物 | 买入 | | 加科思-B | 买入 | 相关研究报告 原料药——①2025-2030 年，下游制剂专利到期影响的销售额为 3900 亿美元，相较 2019-2024 年总额增长 124 ...

【宏观】经济供需关系有所改善——2025 年 5 月经济数据点评 5 月在"以旧换新"政策和节假日带动下，商品和服务消费复苏形势加快，社零表现 大超预期。但是，在 5 月工作日天数较少、美国关税政策、房地产销售跌幅扩大等因 素的扰动下，投资端增速有所下滑，制造业、基建和地产投资增速均有不同程度的回 落。整体来看，5 月表现出需求端加速恢复、投资端增速放缓的格局，经济的供需关 系有所改善。 【金工】医药主题基金表现亮眼，股票型 ETF 资金延续流出——基金市场与 ESG 产 品周报 20250616 本周地缘冲突影响下原油价格延续大涨，国内权益市场指数表现分化，偏股混合型基 金表现领先，股票指数基金小幅下跌。行业主题基金方面，医药主题基金优势延续， 上涨 3.75%，TMT 主题基金净值回撤。股票型 ETF 资金延续流出，资金净流出 154.20 亿元，大盘宽基 ETF 资金净流出明显，港股、商品 ETF 资金呈现流入。行业配置动 向上，石油石化、有色金属、通信等行业获资金增配。 2025 年 6 月 17 日 晨会速递 分析师点评 市场数据 总量研究 行业研究 【交运】中东地缘冲突升级，看好油运景气回升——交 ...

2025 年 06 月 11 日 行业周报 看好/维持 医药 医药 板块持续跑赢大盘，关注后续创新药催化（附 CD73 靶点研究）(2025.06.03-2025.06.08) 走势比较 (20%) (10%) 0% 10% 20% 30% 24/6/11 24/8/22 24/11/2 25/1/13 25/3/26 25/6/6 | 君实生物 | 买入 | | --- | --- | | 华领医药-B | 买入 | | 奥锐特 | 买入 | | 同和药业 | 买入 | | 阳光诺和 | 买入 | | 泓博医药 | 买入 | | 福元医药 | 买入 | | 三生制药 | 买入 | | 京新药业 | 买入 | | 共同药业 | 增持 | | 亿帆医药 | 买入 | | 诺诚健华 | 买入 | | 诺思格 | 买入 | | 奥翔药业 | 买入 | | 科伦药业 | 买入 | | 国邦医药 | 买入 | | 来凯医药-B | 买入 | | 百利天恒 | 买入 | | 益方生物 | 买入 | | 皓元医药 | 买入 | | 普洛药业 | 买入 | | 信达生物 | 买入 | | 加科思-B | 买入 | 子行业评级 ...

证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2025 年 6 月 4 日投资者关系活动记录表 编号：【2025】第 017 号 1 Q2、医未医疗目前有哪些成熟的产品和应用吗？ 公司目前已经有三款主打产品问世，分别是： 医未-脑医生，全球首款应用于 AD 早期诊断的 AI 医疗软件， 已取得国家药品监督管理局 III 类证书及 CE 认证，系国内唯一国际国 内双认证的诊断 AD 的影像 AI 产品。 医未-睿脑，脑卒中急性期一站式 AI 辅助诊断平台，可实现卒 中 AI 诊断全周期、多模块、双影像的认证，已完成国家药品监督管 理局 III 类证及 FDA510k 认证，是国内第一批在 AI 卒中领域完成中 美双认证的产品。 医未-数疗，脑科学数字疗法，是结合临床干预技术，基于眼动 追踪技术、人工智能技术及虚拟现实(VR)技术开发的针对认知功能快 速评估和康复训练的产品。该产品是全国率先融合眼动追踪和 VR 技 术实现认知评估与康复治疗并达临床金标准。 Q3、医未医疗的商业模式是怎样的？ 医未医疗聚焦于脑部疾病精准诊疗领域，其核心产品聚焦卒中、 阿尔茨海默病、认知症、 ...

证券研究报告 行业深度 医疗器械 AI 医疗重构诊疗流程，效率与市场增长下的投资机会 | 2025 年 05 月 13 日 | | | --- | --- | | 评级 | 领先大市 | 评级变动： 维持 行业涨跌幅比较 % 1M 3M 12M 医疗器械 3.41 -2.04 -11.64 沪深 300 3.89 -0.60 6.27 -25% -15% -5% 5% 15% 25% 2024-05 2024-08 2024-11 2025-02 2025-05 医疗器械 沪深300 龙靖宁 分析师 执业证书编号:S0530523120001 longjingning@hnchasing.com 相关报告 1 医疗器械行业 4 月报：国家药监局发布征求意 见稿，全力支持高端医疗器械重大创新 2025-04-15 2 医疗器械行业 3 月报：DeepSeek 加速 AI 医疗 落地，建议关注相关企业投资机遇 2025-03-12 3 医疗器械行业 2 月报：国务院创新药械支持文 件出台，政策红利有望进一步释放 2025-02-10 | 重点股票 | 2024A | | 2025E | | 2026E | | 评 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualan Biological Engineering, and others [4]. Core Viewpoints - The report highlights the investment opportunities in innovative drugs against the backdrop of global asset rebalancing, particularly focusing on KRAS G12C mutation in non-small cell lung cancer (NSCLC) [2][8]. - It emphasizes the potential for KRAS G12C inhibitors to advance to first-line treatment for NSCLC, with an estimated 30% of KRAS mutations in NSCLC being of the G12C subtype, leading to approximately 30,000 new cases annually in China [5][17]. Summary by Sections 1. Industry Viewpoints and Investment Recommendations - KRAS G12C inhibitors are progressing towards first-line treatment for NSCLC, with current standard therapies being PD1 ± chemotherapy [18]. - The report suggests focusing on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market, with significant data releases expected from major conferences [6][32]. 2. Pharmaceutical Industry Market Performance - The pharmaceutical sector saw a 1.01% increase, slightly underperforming the CSI 300 index by 1.00 percentage points [39]. - Sub-sectors such as drug packaging and medical devices performed well, while innovative drugs lagged behind [39]. 3. Company Dynamics - Notable company activities include the approval of new drugs and clinical trial advancements, such as the successful Phase III trials for AstraZeneca's Breztri and Genmab's Epcoritamab [46]. - Companies like Junshi Biosciences and Innovent Biologics are highlighted for their leading positions in the KRAS G12C inhibitor market [22][23]. 4. Industry Dynamics - The report discusses the impact of patent expirations on raw material demand, projecting a significant increase in sales due to the expiration of patents for top-selling small molecule drugs [35]. - It also notes the improvement in demand for raw materials and the end of inventory destocking phases, suggesting a positive outlook for the raw material sector [35].

业绩修复周期开启，双主线聚焦"创新药+AI 医疗" [Table_Industry] 医药生物行业周报 [Table_ReportTime] 2025 年 05 月 06 日 证券研究报告 行业研究 [Table_ReportType] 行业周报 医药生物 医药生物 投资评级 看好 上次评级 看好 [Table_A 唐爱金 uthor 医药首席分析师 ] 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 赵丹 医药行业分析师 执业编号：S1500524120002 邮 箱：zhaodan1@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 ...

行业研究 [Table_ReportType] 行业周报 医药生物 医药生物 业绩修复周期开启，双主线聚焦"创新药+AI 医疗" [Table_Industry] 医药生物行业周报 [Table_ReportTime] 2025 年 05 月 06 日 证券研究报告 投资评级 看好 上次评级 看好 [Table_A 唐爱金 uthor 医药首席分析师 ] 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 赵丹 医药行业分析师 执业编号：S1500524120002 邮 箱：zhaodan1@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term pressure but is expected to improve gradually quarter by quarter [1] - In 2024, the company achieved total revenue of 36.726 billion yuan, a year-on-year increase of 5.14%, and a net profit attributable to shareholders of 11.668 billion yuan, a year-on-year increase of 0.74% [7] - The company anticipates a turning point in 2025, despite short-term challenges in the domestic market [7] Financial Performance Summary - Total revenue projections for the company are as follows: 39.369 billion yuan in 2025, 45.061 billion yuan in 2026, and 52.403 billion yuan in 2027, with respective year-on-year growth rates of 7.20%, 14.46%, and 16.29% [1] - Net profit attributable to shareholders is projected to be 11.960 billion yuan in 2025, 13.131 billion yuan in 2026, and 15.280 billion yuan in 2027, with year-on-year growth rates of 2.50%, 9.79%, and 16.37% [1] - The latest diluted EPS is expected to be 9.86 yuan in 2025, 10.83 yuan in 2026, and 12.60 yuan in 2027 [1] Business Segment Performance - The Life Information and Support business generated revenue of 13.557 billion yuan in 2024, a decrease of 11.11% year-on-year, while the International Life Information and Support business saw double-digit growth [7] - The In Vitro Diagnostics (IVD) business achieved revenue of 13.765 billion yuan, a year-on-year increase of 10.82%, marking its first time exceeding the Life Information and Support business in revenue [7] - The Medical Imaging segment generated revenue of 7.498 billion yuan, with international business growth exceeding 15% [7] - The Electrophysiology and Vascular Intervention segment generated revenue of 1.439 billion yuan, with the acquisition of control over Huitai Medical to enhance cardiovascular segment capabilities [7] Innovation and Growth Drivers - The company launched several innovative products in 2024, including advanced medical systems and AI-driven solutions to improve patient care and operational efficiency [7] - The company maintains a strong competitive position due to its diverse product lines and continuous innovation [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report anticipates a recovery in the pharmaceutical sector in Q2 2025, with a focus on innovative drugs, AI healthcare, and consumer healthcare [2][17] - The report highlights that 52% of pharmaceutical companies have disclosed their Q1 2025 performance, with 35% showing growth in both revenue and net profit [13][17] - The report suggests that the pharmaceutical sector is expected to experience performance recovery due to the gradual digestion of policy impacts and the revival of both inpatient and outpatient markets [17] Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's weekly return was 1.16%, ranking 15th among 31 primary sub-industry indices [11] - The medical services sub-sector had the highest weekly increase of 3.38%, while the bioproducts sub-sector saw a decline of 0.93% [11][31] 2. Performance and Valuation of the Pharmaceutical Sector - The pharmaceutical industry index's current PE (TTM) is 26.25 times, which is below the historical average of 31.15 times [21][24] - The report indicates that the pharmaceutical sector's performance over the last month was -2.19%, with a relative performance of 1.51% compared to the CSI 300 index [27] 3. Market Tracking - The report notes that the chemical pharmaceutical sub-sector had the highest one-year increase of 12.82%, while the pharmaceutical commercial sub-sector experienced the largest decline of 14.33% [34] - The report also highlights that the medical services sub-sector had the highest weekly increase of 3.38% [40] 4. Industry and Company Dynamics - The report discusses recent policy developments, including the implementation plan for the digital transformation of the pharmaceutical industry from 2025 to 2030, aiming for comprehensive digital transformation by 2030 [12][49] - It also mentions significant company announcements, such as clinical trial approvals for various innovative drugs [51]